The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BLRX | -14.61% | -97.87% | -53.63% | -100% |
| S&P | +13.95% | +78.35% | +12.25% | +418% |
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
No news articles found for BioLineRx.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $429.00K | -91.3% |
| Gross Profit | $225.05K | -93.9% |
| Gross Margin | 52.46% | -22.6% |
| Market Cap | $16.11M | -62.4% |
| Market Cap / Employee | $575.46K | 0.0% |
| Employees | 28 | 0.0% |
| Net Income | -$981.57K | 83.1% |
| EBITDA | -$2,097.76K | 53.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.91M | -10.4% |
| Accounts Receivable | $0.00K | -100.0% |
| Inventory | 2.2 | -38.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.60M | -65.7% |
| Short Term Debt | $4.78M | -53.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -6.68% | 31.3% |
| Return On Invested Capital | -103.81% | 4.6% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,591.00K | 81.7% |
| Operating Free Cash Flow | -$2,119.19K | 78.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.42 | 0.70 | 0.82 | 0.80 | -84.08% |
| Price to Sales | 0.63 | 0.49 | 1.04 | 1.28 | -34.21% |
| Price to Tangible Book Value | -144.43 | -1.25 | 1.63 | 1.67 | -99.97% |
| Enterprise Value to EBITDA | -8.83 | 0.76 | -1.15 | -1.23 | -87.04% |
| Return on Equity | -69.3% | -20.2% | -46.6% | -22.0% | -88.12% |
| Total Debt | $15.04M | $13.74M | $12.60M | $11.38M | -61.58% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
